- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Manufacturers and the Cost of Biosimilars and Biologics
Amanda Forys, MSPH: So what if a manufacturer was sitting here and they said, “But hey Christy, I am providing "the As;" I’m giving the patient accessibility, so they might not want to be on the biosimilar because they might not think it’s effective, or they want to be on the biosimilar but still the biosimilar and the biologic originator were both very expensive, [and] neither one is on their formulary. I’m a program offering the patient that assistance,” what do you say to that manufacturer?
Christy M. Gamble, JD, DrPH, MPH: Well, that’s an interesting argument. I would definitely still say that we have to have a conversation about cost here. We have to make sure that we’re putting the patient first. We have to also make sure that we’re not bankrupting taxpayers while we’re trying to get patients these drugs. We want to make sure that patients get the most effective drug, but we also want to make sure that costs are controlled. That’s a discussion that we should be having versus whether or not this patient assistance program should be in existence or not. It’s in existence because of the sky-rocketing price of these drugs.
AON Saves Over $243 Million With High Biosimilar Adoption
April 22nd 2024Thanks to high biosimilar adoption rates within the community oncology setting, American Oncology Network (AON) saved upwards of $243 million between 2020 and 2023, according to a presentation at the Festival of Biologics USA conference in San Diego, California.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Biosimilars Rheumatology Roundup for February 2024—Podcast Edition
March 3rd 2024On this episode of Not So Different, The Center for Biosimilars® revisited all the major rheumatology biosimilar news from February 2024, including the FDA approval of the 10th adalimumab biosimilar, the promise for an oral delivery system for ustekinumab, and the impact of adalimumab products on COVID-19 antibodies.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Global Biosimilar Market Projected to Reach $1.3 Trillion by 2032
April 11th 2024The global biosimilar market is projected to surge from $25.1 billion in 2022 to approximately $1.3 trillion by 2032, with a compound annual growth rate of 17.6%, driven mainly by the increasing prevalence of cancer and the cost-effectiveness of biosimilars, as outlined in a report by Towards Healthcare.
